0 results available. Select is focused ,type to refine list, press Down to open the menu,
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, In...
The following section summarizes insights on Johnson & Johnson's Net Income to Company (Cont. Ops) Growth:
To view the full list of supported financial metrics please see Complete Metrics Listing.
Period over prior period growth in net income to company from continuing operations.
The net income to company (cont. ops) growth measures a company’s net income to company (cont. ops) year-over-year growth. The formula to calculate net income to company (cont. ops) growth and an example calculation for Johnson & Johnson’s trailing twelve months is outlined below:
Net Income to Company (Cont. Ops) Growth = (Current Year - Prior Year) / ABS(Prior Year Net Income to Company (Cont. Ops))*
5.6% = ($14.066 B - $13.326 B) / $13.326 B
*ABS = An absolute value adjustment is used to ensure the direction of growth of negative numbers is reflected
The tables below summarizes Johnson & Johnson’s performance over the last five years:
| Fiscal Year | Net Income to Company (Cont. Ops) | Growth |
|---|---|---|
| 2021-01-03 | 14.714 B | −2.7% |
| 2022-01-02 | 17.801 B | 21.0% |
| 2023-01-01 | 16.37 B | −8.0% |
| 2023-12-31 | 13.326 B | −18.6% |
| 2024-12-29 | 14.066 B | 5.6% |
The tables below summarizes Johnson & Johnson’s performance over the last four quarters:
| Quarter Ending | Net Income to Company (Cont. Ops) | Growth |
|---|---|---|
| 2024-03-31 | 3.255 B | 762.9% |
| 2024-06-30 | 4.686 B | −12.8% |
| 2024-09-29 | 2.694 B | −37.5% |
| 2024-12-29 | 3.431 B | −17.0% |
Growth calculations are always made in the company’s reporting currency to ensure currency fluctuations do not impact the calculation. Johnson & Johnson’s reports in the USD currency. You can read more about Net Income to Company (Cont. Ops) here.
The chart above depicts the distribution of net income to company (cont. ops) growth for companies operating in the Healthcare sector in the Developed economic region. Over 2,460 companies were considered in this analysis, and 2,363 had meaningful values. The average net income to company (cont. ops) growth of companies in the sector is -11.8% with a standard deviation of 125.6%.
Johnson & Johnson's Net Income to Company (Cont. Ops) Growth of 5.6% ranks in the 47.9% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 2,461 |
| Included Constituents | 2,363 |
| Min | -815.5% |
| Max | 425.6% |
| Median | 8.0% |
| Mean | -11.8% |
| Standard Deviation | 125.6% |
You can find companies with similar net income to company (cont. ops) growth using this stock screener.